ZYME compared with ATRA: revenue, margins and what each company keeps, and the suppliers and customers both name

ZYMEZymeworks Inc.

Mkt capRevenueRevenue

ATRAAtara Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

ZYMEZymeworks Inc.

ATRAAtara Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ZYME

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±20.7%▲+1.77%×0.09

May 8 '26±25.0%▼−10.19%×0.41

Q1 FY26±12.9%▲+0.09%×0.01

Jan 13 '26±9.9%▲+3.28%×0.33

ATRA1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−7.75%—

= impliedZYME realized, solidATRA realized, hatchedOne scale, both sides: full bar = 26%× = |realized| ÷ impliedSource: market data

ZYMEZymeworks Inc.

28.59▼−0.44%· post 28.59

Mkt cap$2.1BRevenue$5MQ2 FY26Revenue$106MFY25

ATRAAtara Biotherapeutics, Inc.

8.10▼−5.04%· post 8.10

ClosedOct 30 '26

Mkt cap$80.4MRevenue$630,000Q2 FY26Revenue$121MFY25

Compare

ClosedOct 30 '26

ZYMEZymeworks Inc.

ATRAAtara Biotherapeutics, Inc.

28.59▼−0.44%post 28.59

Price

8.10▼−5.04%post 8.10

$2.1B

Mkt cap

$80.4M

Q2 FY26$5M

Revenue

$630,000Q2 FY26

FY25$106M

Revenue

$121MFY25

ZYME28.59▼−0.44%vsATRA8.10▼−5.04%ClosedOct 30 '26